The Business Of Neurotech cover art

The Business Of Neurotech

The Business Of Neurotech

By: Adam Fraser
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary

From breakthrough devices to the bottom line. The Business of Neurotech is the premier podcast dedicated to the commercial trends, investment strategies, and innovative business models shaping the neuroscience economy. Hosted by Adam Fraser, this series moves beyond the lab to explore how groundbreaking research in neuromodulation, BCI, and medical devices is transformed into viable, scalable enterprises. +2 Each episode features candid, fireside-chat interviews with the ecosystem's most influential voices—from founders and CEOs to venture capitalists and strategic leaders. We dive into the "how" and "why" behind the headlines, discussing market maturity, regulatory hurdles, and the go-to-market strategies required to bring neurotechnology to the global stage. +3 Whether you are an investor conducting due diligence, a researcher exploring commercial applications, or an entrepreneur building the next generation of brain-tech, this show provides the strategic insights you need to navigate the future of the sector.

© 2026 Copyright 2026 - The Business of Neurotech
Biological Sciences Economics Science
Episodes
  • Dorian Haci talks Neurotech Chips and BCI
    Nov 16 2026

    What will it take to make neurotechnology part of everyday life? In this episode, Adam Fraser is joined by Dorian Haci, co-founder and CEO of MintNeuro, to explore the business behind the chips that power neural devices and BCIs. In their conversation, Dorian shares his perspective on building a company that helps other innovators move forward and turns scientific ambition into something people can use. They explore his ambition to make neurotech more accessible, the importance of creating real-world value and the possibilities of a closer relationship with technology. They also delve into the drive to solve meaningful problems, the value of learning from others and the long-term view behind lasting innovation. Tune in to learn about the decisions and relationships shaping neurotech’s next chapter.

    Key Points From This Episode:

    • [01:33] Meet Dorian and hear how his electronics background led him to MintNeuro.
    • [02:56] Discover why Dorian chose to use electronics to address neurological conditions.
    • [03:58] Learn why hardware bottlenecks caused MintNeuro’s move out of academia.
    • [06:17] Understand how neurotech chips differ from processors used for computing.
    • [09:22] Explore why MintNeuro builds modular, function-specific chips for neural devices.
    • [12:25] Hear why Dorian favours close customer partnerships over selling off-the-shelf chips.
    • [16:16] Unpack how he defines the BCI landscape and its place within wider neurotech.
    • [22:05] Where companies could compete as the BCI supply chain becomes specialised.
    • [27:31] Uncover why investors are backing BCI despite its long path to commercial scale.
    • [31:13] Assess how grants and investors have supported MintNeuro’s progress to market.
    • [33:41] MintNeuro's funding requirements and their strategy for scaling globally.
    • [36:33] Find out how Dorian adapted from designing chips to leading a business.
    • [39:33] Final takeaways and how to connect with Dorian and follow MintNeuro’s progress.

    Links Mentioned in Today’s Episode:

    Dorian Haci on LinkedIn

    MintNeuro

    MintNeuro on LinkedIn

    Motif

    Amber Therapeutics

    Episode 5: Naveen Rao Talks Neurotech Market Dynamics

    Phase Lock

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast

    Show More Show Less
    40 mins
  • Daniel Månsson Talks tDCS, Depression and Scaling a Start Up
    Nov 2 2026

    Flow Neuroscience has developed an at-home brain stimulation treatment for depression, but bringing it to market has involved years of clinical research, regulatory approvals, and commercial challenges. In this episode of the Business of Neurotech Podcast, host Adam Fraser welcomes Daniel Månsson, Co-founder and CEO of Flow Neuroscience, to explore the story behind the technology and the company's expansion into the U.S. market. Daniel explains how his background in clinical psychology led him to start the company, how transcranial direct current stimulation (tDCS) works, and the benefits and challenges of the company’s early direct-to-consumer model in Europe. He shares how clinical trials helped secure FDA approval and how Flow is approaching its recent U.S. launch. The discussion also covers the company's funding journey, the challenges of moving from research to commercial growth, and its long-term ambitions. Listen in to hear Daniel's vision for making depression treatment more accessible and discover how precision psychiatry could help match patients with the treatments most likely to work for them.

    Key Points From This Episode:

    • [01:11] How Daniel’s diverse career background led him to co-found Flow Neuroscience.
    • [02:09] Daniel's perspective on the challenges of diagnosing and treating depression.
    • [05:32] What inspired Daniel to found Flow Neuroscience with his partner.
    • [08:31] How tDCS works, compares with other treatments, and is used in Flow's headset.
    • [13:41] Flow's early direct-to-consumer model in Europe and its benefits and challenges.
    • [15:53] Why Flow was perceived as a wellness product despite its clinical evidence.
    • [17:54] Understand what it took to bring Flow's technology into the U.S. market.
    • [19:29] How Flow's U.S. prescription model differs from its European approach.
    • [21:37] Unpack the clinical trial results that helped Flow secure FDA approval.
    • [25:28] Hear about Flow's ongoing research into other potential treatment applications.
    • [27:17] Explore Flow's funding journey and the challenges of scaling a science-led business.
    • [32:10] Daniel's long-term vision for Flow and the potential of precision psychiatry.
    • [34:00] Find out how to connect with Daniel and learn more about Flow Neuroscience.

    Links Mentioned in Today’s Episode:

    Daniel Månsson on LinkedIn

    Flow Neuroscience

    Flow Neuroscience | Research and Clinical Trials

    Empower Clinical Trial — Nature Medicine

    Khosla Ventures

    Episode 4: Mariam Khayretdinova talks EEG, AI and Psychiatry

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    35 mins
  • Chay Carter Talks Neurotech Recruitment and Market Trends
    Oct 19 2026

    What can the people building neurotech teams tell us about where the industry is heading? In this episode of The Business of Neurotech, Adam Fraser speaks with Chay Carter, founder of Carter Sciences and co-founder of reccy neuro, to offer a recruitment-focused view of the sector. Chay brings decades of experience in recruitment and psychology, combining specialist hiring with research, newsletters and insights from the people developing the technology. In their conversation, Chay shares how he came to focus on neurotech and what he has learnt about helping companies build the teams they need. They also discuss the influence of AI on recruitment, the broader trends he is seeing across neurotech and how his research and media work connect with the changing needs of the industry. Tune in for Chay’s perspective on people, relationships and how the market is shaping neurotech’s next chapter.

    Key Points From This Episode:

    • [01:24] Trace how Chay’s career led to specialist neurotech recruitment and reccy neuro.
    • [07:37] Discover what makes a strong founding team beyond scientific and technical talent.
    • [09:39] Learn how hiring priorities change as startups move towards commercialisation.
    • [12:03] Understand why big-company experience can be a shock to the system at a startup.
    • [13:59] Explore how market trends shape his recruitment and fractional support for startups.
    • [18:39] Examine where AI, BCI, and implantable devices are changing the demand for talent.
    • [21:07] Hear why AI applications and screening still require real human conversations.
    • [23:46] Consider whether AI can replace the hands-on work neurotech companies need.
    • [25:24] Follow how Chay transforms global news into newsletters, interviews, and deep dives.
    • [29:26] Unpack the scale and pace of neurotech’s growth and difficulties defining the sector.
    • [31:50] Assess how his media and market data could become a business in their own right.
    • [34:53] Compare US dominance with the neurotech activity happening around the world.
    • [38:04] Find out why wearable brain-reading devices still face a form factor challenge.
    • [39:05] Connect with Chay and access his research and free neurotech company database.

    Links Mentioned in Today’s Episode:

    Chay Carter on LinkedIn

    Carter Sciences

    reccy neuro

    Carter Sciences | The Neurotech Newsletter

    The Open Loop Podcast

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    40 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.